

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM480345

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
ROMARK BIOSCIENCES S.À R.L. LLC		06/28/2018	SOCIÉTÉ À RESPONSABILITÉ LIMITÉE: LUXEMBOURG
ROMARK LABORATORIES, L.C.		06/28/2018	Limited Liability Company: FLORIDA
RECEIVING PARTY DATA			
Name:	U.S. BANK NATIONAL ASSOCIATION		
Street Address:	ONE FEDERAL STREET, 3RD FLOOR		
City:	BOSTON		
State/Country:	MASSACHUSETTS		
Postal Code:	02110		
Entity Type:	National Banking Association: UNITED STATES		
PROPERTY NUMBERS Total: 5			
Property Type	Number	Word Mark	
Registration Number:	5459540	ROMARK	
Serial Number:	86474020	WILINTRIS	
Serial Number:	86473969	QUILIK	
Serial Number:	86473935	QUILIC	
Registration Number:	2812956	ALINIA	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	8585094071		
Email:	sdipdocket@pillsburylaw.com		
Correspondent Name:	Michelle L. Mehok		
Address Line 1:	12255 El Camino Real, Suite 300		
Address Line 4:	San Diego, CALIFORNIA 92130		
ATTORNEY DOCKET NUMBER:	258340-0166		
NAME OF SUBMITTER:	Michelle L. Mehok		

CH \$140.00 5459540

SIGNATURE:	/michelle mehok/
DATE SIGNED:	07/02/2018
Total Attachments: 15 source=Romark 2018 - June#page1.tif source=Romark 2018 - June#page2.tif source=Romark 2018 - June#page3.tif source=Romark 2018 - June#page4.tif source=Romark 2018 - June#page5.tif source=Romark 2018 - June#page6.tif source=Romark 2018 - June#page7.tif source=Romark 2018 - June#page8.tif source=Romark 2018 - June#page9.tif source=Romark 2018 - June#page10.tif source=Romark 2018 - June#page11.tif source=Romark 2018 - June#page12.tif source=Romark 2018 - June#page13.tif source=Romark 2018 - June#page14.tif source=Romark 2018 - June#page15.tif	

AMENDED AND RESTATED TRADEMARK COLLATERAL AGREEMENT

This AMENDED AND RESTATED TRADEMARK COLLATERAL AGREEMENT (“Agreement”) is dated as of June 28, 2018, by and among **ROMARK BIOSCIENCES S.À R.L. LLC**, a *société à responsabilité limitée* organized and existing under the laws of Luxembourg, having its registered office at 1A, rue Thomas Edison, L-1445 Strassen, Grand Duchy of Luxembourg and registered with the Luxembourg Register of Commerce and Companies (R.C.S. Luxembourg) under number B 188332 (the “Luxembourg Issuer”), **ROMARK LABORATORIES, L.C.**, a Florida limited liability company having an address at 3000 Bayport Drive #200, Tampa, Florida 33607 (the “Parent” and, together with the Luxembourg Issuer, the “Grantors” and each, a “Grantor”), and **U.S. BANK NATIONAL ASSOCIATION**, in its capacity as collateral agent for the Secured Parties (as defined below) with the address listed below (and its successors under the Indenture, in such capacity, the “Collateral Agent”).

PRELIMINARY STATEMENT

WHEREAS the Grantors, among others, have entered into that certain Amended and Restated Indenture dated as of the date hereof (as amended, extended, renewed, restated, supplemented, waived or otherwise modified from time to time, the “Indenture”) with the Collateral Agent and U.S. BANK NATIONAL ASSOCIATION, in its capacity as Trustee having an address at One Federal Street, 3rd Floor, Boston, Massachusetts 02110 (and its successors under the Indenture (as defined below), in such capacity, the “Trustee”);

WHEREAS, as a condition to the issuance by the Luxembourg Issuer and/or Romark Global Pharma, LLC of its respective 11% Senior Secured Notes, each of the Grantors has entered into that certain Amended and Restated Collateral Agreement dated as of the date hereof (as may be amended, extended, renewed, restated, supplemented, waived or otherwise modified from time to time, the “Collateral Agreement”); and

WHEREAS, pursuant to the terms of the Collateral Agreement, each of the Grantors has agreed to grant to the Collateral Agent, for the benefit of the Secured Parties (as defined in the Collateral Agreement), a continuing security interest in and lien on, such Grantor’s right, title and interest in and to all present and future copyrights, patents, trademarks, and related licenses and rights for the benefit of the Secured Parties; and

WHEREAS, pursuant to the Collateral Agreement, each of the Grantors is required to execute and deliver to the Collateral Agent this Agreement.

NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each of the Grantors hereby agrees as follows:

I. **DEFINED TERMS.** All capitalized terms used but not otherwise defined herein have the meanings given to them in the Collateral Agreement.

II. GRANT OF SECURITY INTEREST IN TRADEMARK COLLATERAL. Each Grantor hereby grants to the Collateral Agent, for the benefit of the Secured Parties, on the terms set forth in and subject to the Collateral Agreement, a continuing first-priority lien and security interest (subject to Permitted Liens) in all of such Grantor's right, title and interest in, to and under the following, whether presently existing or hereafter created or acquired (collectively, the "Trademark Collateral"):

A. all of its trademark applications and registrations set forth in Schedule I hereto, excluding any application for registration of a trademark filed on an intent-to-use basis solely to the extent that the grant of a security interest in any such trademark application would adversely affect the validity or enforceability of the resulting trademark registration or result in cancellation of such trademark application (the "Trademarks");

B. all goodwill of the business associated with the Trademarks; and

C. all products and proceeds of the Trademarks, including any claim by such Grantor against third parties for past, present or future (i) infringement or dilution of any Trademarks or any Trademarks exclusively licensed under any intellectual property license, including the right to receive any damages, (ii) injury to the goodwill associated with any Trademark or (iii) right to receive license fees, royalties and other compensation under any intellectual property license;

provided, however, that, notwithstanding anything herein to the contrary, the Trademark Collateral shall not include, and the lien and security interest granted in this Agreement shall not attach to, any and all Excluded Assets.

III. SECURITY FOR OBLIGATIONS. The grant of a lien and security interest in the Trademark Collateral by the Grantors pursuant to this Agreement secures prompt payment to the Secured Parties of the Obligations. This Agreement and the lien and security interest created hereby secures the payment and performance of the Obligations, whether now existing or arising hereafter. Without limiting the generality of the foregoing, this Agreement secures the payment of all amounts which constitute part of the Obligations (as defined in the Collateral Agreement) and would be owed by the Grantors to the Secured Parties, whether or not they are unenforceable or not allowable due to the existence of a proceeding commenced by or against any Grantor under any provision of the Bankruptcy Code (or under any other applicable foreign bankruptcy, insolvency, receivership or similar law) or under any other state or federal bankruptcy or insolvency law, assignments for the benefit of creditors, formal or informal moratoria, compositions, extensions generally with creditors, or proceedings seeking reorganization, arrangement, or other similar relief.

IV. COLLATERAL AGREEMENT. The lien and security interest granted pursuant to this Agreement is granted in conjunction with the lien and security interests granted to the Collateral Agent pursuant to the Collateral Agreement. Each Grantor hereby acknowledges and affirms that the rights and remedies of the Collateral Agent with respect to the lien and security interest in the Trademark Collateral made and granted hereby are more fully set forth in the Collateral Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. To the extent there is any inconsistency between this Agreement and the Collateral Agreement, the Collateral Agreement shall control.

V. AUTHORIZATION TO SUPPLEMENT. Each Grantor hereby authorizes the Collateral Agent to modify this Agreement by amending Schedule I to include any new trademark rights of such Grantor in accordance with the provisions of the Collateral Agreement; provided, that, the Collateral Agent shall provide prior written notice to the Grantors of any such amendment or modification, including a copy of the proposed amendment or modification to Schedule I. Notwithstanding the foregoing, no failure to so modify this Agreement or amend Schedule I or provide notice to the Grantors of same shall in any way affect, invalidate or detract from the Collateral Agent's continuing security interest in all Collateral, whether or not listed on Schedule I.

VI. LIMITATION BY LAW; SEVERABILITY OF PROVISIONS. All rights, remedies and powers provided in this Agreement may be exercised only to the extent that the exercise thereof does not violate any applicable provision of law, and all the provisions of this Agreement are intended to be subject to all applicable mandatory provisions of law that may be controlling and to be limited to the extent necessary so that they shall not render this Agreement invalid, unenforceable or not entitled to be recorded or registered, in whole or in part. The illegality or unenforceability of any provision of this Agreement or any instrument or agreement required hereunder shall not in any way affect or impair the legality or enforceability of the remaining provisions of this Agreement or any instrument or agreement required hereunder.

VII. BINDING EFFECT. The provisions of this Agreement shall be binding upon and inure to the benefit of the respective representatives, successors, and permitted assigns of the parties hereto; provided, however, neither Grantor shall assign or delegate any of its rights or duties under this Agreement without the prior written consent of the Collateral Agent (other than pursuant to a transaction permitted under the Indenture), and any attempted assignment without such consent shall be null and void. The rights and benefits of the Collateral Agent hereunder shall, if such Persons so agree, inure to any party acquiring any interest in the Obligations or any part thereof in accordance with the terms hereof or of the Collateral Agreement.

VIII. CAPTIONS. The captions contained in this Agreement are for convenience of reference only, are without substantive meaning and should not be construed to modify, enlarge, or restrict any provision.

IX. TERMINATION AND RELEASE. This Agreement shall terminate in accordance with the Collateral Agreement.

X. ENTIRE AGREEMENT. This Agreement, together with the Collateral Agreement, other Indenture Documents and the other Security Documents, embodies the entire agreement and understanding between the Grantors and the Collateral Agent relating to the Trademark Collateral and supersedes all prior agreements and understandings between the Grantors and the Collateral Agent relating to the Trademark Collateral.

XI. COUNTERPARTS. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one agreement, and any of the parties hereto may execute this Agreement by signing any such counterpart, and a copy of any such counterpart shall be valid as an original.

XII. AMENDMENTS. Other than as permitted pursuant to the Collateral Agreement, neither this Agreement nor any provision hereof may be waived, amended or modified except pursuant to an agreement or agreements in writing entered into by the Collateral Agent and the Grantors with respect to which such waiver, amendment or modification is to apply, subject to any consent that may be required in accordance with the Collateral Agreement.

XIII. GOVERNING LAW. **THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAW (OTHER THAN SECTIONS 5-1401 AND 5-1402 OF THE NEW YORK GENERAL OBLIGATIONS LAW) EXCEPT TO THE EXTENT THAT LOCAL LAW GOVERNS THE CREATION, PERFECTION, PRIORITY OR ENFORCEMENT OF SECURITY INTERESTS.**

XIV. AMENDMENT AND RESTATEMENT. This Agreement amends and restates that certain Trademark Collateral Agreement dated as of December 22, 2017 among the Luxembourg Issuer, the Parent and the Collateral Agent (the “Original Agreement”). It is the intent of the parties that the amendment and restatement of the Original Agreement shall not constitute a novation and that the security interests and Liens granted in the Trademark Collateral under and pursuant to the Original Agreement shall continue in full force and effect.

[signature page follows]

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

ROMARK BIOSCIENCES S.À R.L. LLC

By:  _____

Name: Marc S. Ayers

Title: Director and Class A Manager

ROMARK LABORATORIES, L.C.

By:  _____

Name: Marc S. Ayers

Title: President and Chief Executive Officer


ACCEPTED AND ACKNOWLEDGED BY:

U.S. BANK NATIONAL ASSOCIATION,

as Collateral Agent

One Federal Street, 3rd Floor

Boston, Massachusetts 02110

By: 

Name: Alison D.B. Nadeau

Title: Vice President

[Amended and Restated Trademark Collateral Agreement]

TRADEMARK
REEL: 006402 FRAME: 0917

Schedule 1
to
TRADEMARK COLLATERAL AGREEMENT

Trademarks

As of June 28, 2018, all of the Trademarks of the Parent are listed below and are held by the Parent for purposes of ownership of bare legal title but are licensed by the Parent to the Luxembourg Issuer pursuant to that certain Worldwide Intellectual Property Agreement effective as of March 6, 2015 among the Parent, Romark Global Pharma, LLC (f/k/a Romark Laboratories, LLC) and the Luxembourg Issuer. In addition, all of the Trademarks listed below are sublicensed by the Luxembourg Issuer to Romark Global Pharma, LLC (f/k/a Romark Laboratories, LLC) pursuant to that certain Sublicense Agreement effective as of March 6, 2015 between the Luxembourg Issuer and Romark Global Pharma, LLC (f/k/a Romark Laboratories, LLC).

Hit No.	Mark/Source/Status	Application Date/Data	Goods	Owner Name
US	ROMARK USPTO Registered	App 02-MAR-2016 App 86/926,642 Reg 01-MAY-2018 Reg 5,459,540	Int'l Class 5 Pharmaceutical preparation for the treatment of influenza or other respiratory infection; Pharmaceuticals, namely, anti-infectives Int'l Class 42 Providing medical and scientific research information in the field of pharmaceuticals; pharmaceutical product development; pharmaceutical research and development	ROMARK LABORATORIES, L.C.
US-1	WILINTRIS USPTO Madrid Basic Application No. 1252230 Pending Application	App 08-DEC-2014 App 86/474,020	Int'l Class 5 Pharmaceutical preparation for the treatment of influenza or other respiratory infection	ROMARK LABORATORIES, L.C.
US-2	QUILIK USPTO Madrid Basic Application No. 1252229 Pending Application	App 08-DEC-2014 App 86/473,969	Int'l Class 5 Pharmaceutical preparation for the treatment of influenza or other respiratory infection	ROMARK LABORATORIES, L.C.

Hit No.	Mark/Source/Status	Application Date/Data	Goods	Owner Name
US-3	QUILIC USPTO Pending Application	App 08-DEC-2014 App 86/473,935	Int'l Class 5 Pharmaceutical preparation for the treatment of influenza or other respiratory infection	ROMARK LABORATORIES, L.C.
US-4	ALINIA USPTO Registered	App 25-NOV-2002 App 78/188,660 Reg 10-FEB-2004 Reg 2,812,956	Int'l Class 5 Pharmaceuticals, namely, anti-infective	ROMARK LABORATORIES, L.C.
CR-1	ALINIA Costa Rica Pending Application	App 30-APR-2003 App 2003-0002546 Also referred to as No. 143984	Computer Translation: 05 Products pharmaceutical against contagious disease.	ROMARK LABORATORIES, L.C.
CR-2	CRYPTAZ Costa Rica Pending Application	App 08-MAY-2001 App 2001-3331	Computer Translation: 05 Pharmaceutical preparations for human use, namely, antibiotic agents and pesticide.	ROMARK LABORATORIES, L.C.
SV-1	ALINIA El Salvador Pending Application	App 05-MAY-2003 App 2003032093 Also referred to as No. 173	N/A	ROMARK LABORATORIES, L.C.
GT-1	ALINIA Guatemala Registered	App 28-MAY-2003 App 200303483 Reg 23-NOV-2004 Reg 133209	Computer Translation: 05 Products pharmaceutical anti - infectious.	ROMARK LABORATORIES, L.C.
GT-2	CRYPTAZ Guatemala Registered	App 04-OCT-2001 App 200107293 Reg 11-MAR-2002 Reg 116069	Computer Translation: 05 Antibiotic agents and pesticide, than pharmaceutical preparations, for exclusive human use.	ROMARK LABORATORIES, L.C.
HN-1	ALINIA Honduras Pending Application	App 05-MAY-2003 App 03010812 Also referred to as No. 91166	Computer Translation: 05 Pharmaceutical products, against contagious (anti infectious)	ROMARK LABORATORIES, L.C.
NI-1	ALINIA Nicaragua Registered	App 05-MAY-2003 App 2003-00001340 Reg 28-JUL-2004 Reg 70624	Computer Translation: 05 Products pharmaceutical against contagious.	ROMARK LABORATORIES, L.C.
NI-2	CRYPTAZ Nicaragua Registered	App 08-FEB-2001 App 2001-00000502 Reg 11-SEP-2001 Reg 51087	Computer Translation: 05 Goods, goods or services, consisting of: pharmaceutical preparations for human use, mainly agents antibiotics and pesticide.	ROMARK LABORATORIES, L.C.

Hit No.	Mark/Source/Status	Application Date/Data	Goods	Owner Name
PA-1	ALINIA Panama Registered	App 07-MAY-2003 App 126982 Reg 07-MAY-2003 Reg 126982	Computer Translation: Pharmaceutical preparations, against contagious (anti ~infective~)	ROMARK LABORATORIES, L.C.
PA-2	CRYPTAZ Panama Registered	App 21-FEB-2001 App 112991 Reg 21-FEB-2001 Reg 112991	Computer Translation: Pharmaceutical preparations for human use, namely, a agent antibiotics. and ~antiparasitico~	ROMARK LABORATORIES, L.C.
	ALINIA Argentina Registered	App 10-SEP-2014 App 3353790 Reg 7-APR-2017 Reg 2882921	5	ROMARK LABORATORIES, L.C.
BO-1	ALINIA Bolivia Registered	App 23-MAY-2003 App 1682-2003 Reg 31-MAY-2006 Reg 103802 C	Computer Translation: Product pharmacist anti infectious.	ROMARK LABORATORIES, L.C.
BO-2	ROMARK Bolivia Registered	App 12-SEP-2002 App 2941-2002 Reg 07-APR-2004 Reg 93800 C	Computer Translation: Pharmaceutical preparations	ROMARK LABORATORIES, L.C.
CL-1	ALINIA Chile Registered	App 02-MAY-2003 App 606279 Reg 05-APR-2007 Reg 783774	Computer Translation: 05 incl. all goods of class.	ROMARK LABORATORIES, L.C.
CL-2	CRYPTAZ Chile Registered	App 27-FEB-2001 App 519038 Reg 15-JAN-2002 Reg 617172	Computer Translation: 05 incl. all goods of classes.	ROMARK LABORATORIES, L.C.
CO-1	ALINIA Colombia Registered	App 26-MAY-2003 App 03 44311 Reg 28-FEB-2005 Reg 338908	Computer Translation: 05 Pharmaceutical anti infectious.	ROMARK LABORATORIES, L.C.
EC-1	ALINIA Ecuador Pending Application	App 21-APR-2003 Reg 133135	Computer Translation: All goods included within of worldwide classes ~n ^o ~ 5, specially concerning products pharmaceutical against contagious disease (anti infectious).	ROMARK LABORATORIES, L.C.
EC-2	CRYPTAZ Ecuador Registered	App 07-JAN-2001 App 111192 Reg 12-DEC-2001 Reg 14244	N/A	ROMARK LABORATORIES, L.C.
PY-1	ALINIA Paraguay Registered	App 12-MAY-2003 App 319257 Reg 05-NOV-2003 Reg 263257	N/A	ROMARK LABORATORIES, L.C.

Hit No.	Mark/Source/Status	Application Date/Data	Goods	Owner Name
PE-1	ALINIA Peru Registered	App 03-DEC-2002 App 168163-2002 Reg 12-JUN-2003 Reg P00089378	Computer Translation: 05 Products pharmaceutical against contagious disease (anti infectious)	ROMARK LABORATORIES, L.C.
UY-1	CRYPTAZ Uruguay Registered	App 29-MAY-2001 App 331682 Reg 26-OCT-2001 Reg 331682	Computer Translation: Pharmaceutical preparations for use within humans particularly, antibiotic agents and pesticide.	ROMARK LABORATORIES, L.C.
VE-1	ALINIA Venezuela Pending Application	App 02-MAY-2003 App 2003-005370 Reg 1267453	Computer Translation: Products pharmaceutical anti - infectious.	ROMARK LABORATORIES, L.C.
VE-2	CRYPTAZ Venezuela Registered	App 08-FEB-2001 App 2001-002000 Reg 28-JUN-2002 Reg P238036	Computer Translation: Pharmaceutical preparations for human use as agents antibiotics and pesticide.	ROMARK LABORATORIES, L.C.
DO-1	ALINIA Dominican Republic Pending Application	App 08-MAY-2003 App 29581 Also referred to as No. 138176	N/A	ROMARK LABORATORIES, L.C.
DO-2	CRYPTAZ Dominican Republic Pending Application	App 13-MAR-2001 App 99200090	N/A	ROMARK LABORATORIES, L.C.
	ALINIA Benelux Registered	Reg 0731006	N/A	ROMARK LABORATORIES, L.C.
	ALINIA Mexico Registered	Reg 825496	N/A	ROMARK LABORATORIES, L.C.
	ALINIA Madrid Protocol Registered	App 26-MAY-2003 App 806515 Reg 26-MAY-2003 Reg 806515	Pharmaceuticals, namely, anti-infectives	LABORATORIA ROMARK NV
	ALINIA Uruguay Registered	Reg 731006	N/A	ROMARK LABORATORIES, L.C.
	QUILIK Australia Registered	App 25-APR-2015 App 1252229 Reg 1701158 Int'l Reg 1252229	Int'l Class 5 Pharmaceutical preparation for the treatment of influenza or other respiratory infection	ROMARK LABORATORIES, L.C.
	QUILIK Japan Registered	App 25-APR-2015 App 1252229 Reg 25-APR-2015 Int'l Reg 1252229	Int'l Class 5 Pharmaceutical preparation for the treatment of influenza or other respiratory infection	ROMARK LABORATORIES, L.C.

Hit No.	Mark/Source/Status	Application Date/Data	Goods	Owner Name
	WILINTRIS Australia Registered	App 24-APR-2015 App 1252230 Reg 1701159 Int'l Reg 1252230	Int'l Class 5 Pharmaceutical preparation for the treatment of influenza or other respiratory infection	ROMARK LABORATORIES, L.C.
	WILINTRIS Japan Registered	App 24-APR-2015 App 1252230 Reg 24-APR-2015 Int'l Reg 1252230	Int'l Class 5 Pharmaceutical preparation for the treatment of influenza or other respiratory infection	ROMARK LABORATORIES, L.C.
	WILINTRIS Brazil Registered	App 22-MAY-2015 App 909419310 Reg 10-OCT-2017 Reg 909419310	Int'l Class 5 Pharmaceutical preparation for the treatment of influenza or other respiratory infection	ROMARK LABORATORIES, L.C.
	WILINTRIS Canada Pending Application	App 27-APR-2015 App 1725990	Int'l Class 5 Pharmaceutical preparation for the treatment of influenza or other respiratory infection	ROMARK LABORATORIES, L.C.
	WILINTRIS China Registered	App 24-APR-2015 App 1252230 Reg 24-APR-2015 Int'l Reg 1252230	Int'l Class 5 Pharmaceutical preparation for the treatment of influenza or other respiratory infection	ROMARK LABORATORIES, L.C.
	WILINTRIS European Union Registered	App 24-APR-2015 App 1252230 Reg 24-APR-2015 Int'l Reg 1252230	Int'l Class 5 Pharmaceutical preparation for the treatment of influenza or other respiratory infection	ROMARK LABORATORIES, L.C.
	WILINTRIS New Zealand Registered	App 24-APR-2015 App 1252230 Reg 24-APR-2015 Reg 1021816 Int'l Reg 1252230	Int'l Class 5 Pharmaceutical preparation for the treatment of influenza or other respiratory infection	ROMARK LABORATORIES, L.C.
	WILINTRIS South Korea Registered	App 24-APR-2015 App 1252230 Reg 24-APR-2015 Int'l Reg 1252230	Int'l Class 5 Pharmaceutical preparation for the treatment of influenza or other respiratory infection	ROMARK LABORATORIES, L.C.

Hit No.	Mark/Source/Status	Application Date/Data	Goods	Owner Name
	WILINTRIS Madrid Protocol Registered	App 24-APR-2015 App 1252230 Reg 24-APR-2015 Int'l Reg 1252230	Int'l Class 5 Pharmaceutical preparation for the treatment of influenza or other respiratory infection	ROMARK LABORATORIES, L.C.
	WILINTRIS Mexico Registered	App 24-APR-2015 App 1252230 Reg 24-APR-2015 Reg 1639958 Int'l Reg 1252230	Int'l Class 5 Pharmaceutical preparation for the treatment of influenza or other respiratory infection	ROMARK LABORATORIES, L.C.
	ROMARK Australia Registered	Reg 1767309	Int'l Classes 5 and 42	ROMARK LABORATORIES, L.C.
	ROMARK Brazil Registered	App 9-MAR-2016 App 910734909 Reg 910734909	Int'l Class 5	ROMARK LABORATORIES, L.C.
	ROMARK Canada Pending Application	App 10-MAR-2016 App 1772375	Int'l Class 5 Pharmaceuticals, namely, anti-infectives; Pharmaceutical preparation for the treatment of influenza or other respiratory infection. Int'l Class 42 Providing medical and scientific research information in the field of pharmaceuticals; pharmaceutical product development; pharmaceutical research and development	ROMARK LABORATORIES, L.C.
	ROMARK China Registered	App 4-Mar-2016 App 1296238 Reg 4-Mar-2016 Int'l Reg 1296238	Int'l Class 5 Pharmaceutical preparation for the treatment of influenza or other respiratory infection; Pharmaceuticals, namely, anti-infectives	ROMARK LABORATORIES, L.C.

Hit No.	Mark/Source/Status	Application Date/Data	Goods	Owner Name
	ROMARK European Community Registered	App 4-Mar-2016 App 1296238 Reg 4-Mar-2016 Int'l Reg 1296238	Int'l Class 5 Pharmaceutical preparation for the treatment of influenza or other respiratory infection; Pharmaceuticals, namely, anti-infectives	ROMARK LABORATORIES, L.C.
	ROMARK Japan Registered	App 4-Mar-2016 App 1296238 Reg 4-Mar-2016 Int'l Reg 1296238	Int'l Class 5 Pharmaceutical preparation for the treatment of influenza or other respiratory infection; Pharmaceuticals, namely, anti-infectives Int'l Class 42 Providing medical and scientific research information in the field of pharmaceuticals; pharmaceutical product development; pharmaceutical research and development	ROMARK LABORATORIES, L.C.
	ROMARK South Korea Registered	App 4-Mar-2016 App 1296238 Reg 4-Mar-2016 Int'l Reg 1296238	Int'l Class 5 Pharmaceutical preparation for the treatment of influenza or other respiratory infection; Pharmaceuticals, namely, anti-infectives Int'l Class 42 Providing medical and scientific research information in the field of pharmaceuticals; pharmaceutical product development; pharmaceutical research and development	ROMARK LABORATORIES, L.C.

Hit No.	Mark/Source/Status	Application Date/Data	Goods	Owner Name
	ROMARK Madid Protocol Registered	App 4-Mar-2016 App 1296238 Reg 4-Mar-2016 Reg 1296238	Int'l Class 5 Pharmaceutical preparation for the treatment of influenza or other respiratory infection; Pharmaceuticals, namely, anti-infectives Int'l Class 42 Providing medical and scientific research information in the field of pharmaceuticals; pharmaceutical product development; pharmaceutical research and development	ROMARK LABORATORIES, L.C.
	ROMARK Mexico Registered	App 4-Mar-2016 App 1296238 Reg 4-Mar-2016 Int'l Reg 1296238 Reg 1752044	Int'l Class 5 Pharmaceutical preparation for the treatment of influenza or other respiratory infection; Pharmaceuticals, namely, anti-infectives	ROMARK LABORATORIES, L.C.
	ROMARK New Zealand Registered	App 4-Mar-2016 App 1296238 Reg 4-Mar-2016 Int'l Reg 1296238 Reg 1041942	Int'l Class 5 Pharmaceutical preparation for the treatment of influenza or other respiratory infection; Pharmaceuticals, namely, anti-infectives Int'l Class 42 Providing medical and scientific research information in the field of pharmaceuticals; pharmaceutical product development; pharmaceutical research and development	ROMARK LABORATORIES, L.C.
	QUILIK Brazil Pending Application	App 22-MAY-2015 App 909419213	Int'l Class 5	ROMARK LABORATORIES, L.C.
	QUILIK Canada Pending Application	App 27-APR-2015 App 1725989	Int'l Class 5 Pharmaceutical preparation for the treatment of influenza or other respiratory infection	ROMARK LABORATORIES, L.C.

Hit No.	Mark/Source/Status	Application Date/Data	Goods	Owner Name
	QUILIK China Registered	App 25-APR-2015 App 1252229 Reg 25-APR-2015 Int'l Reg 1252229	Int'l Class 5 Pharmaceutical preparation for the treatment of influenza or other respiratory infection	ROMARK LABORATORIES, L.C.
	QUILIK European Community Registered	App 25-APR-2015 App 1252229 Reg 25-APR-2015 Int'l Reg 1252229	Int'l Class 5 Pharmaceutical preparation for the treatment of influenza or other respiratory infection	ROMARK LABORATORIES, L.C.
	QUILIK South Korea Registered	App 25-APR-2015 App 1252229 Reg 25-APR-2015 Reg 1252229 Int'l Reg 1252229	Int'l Class 5 Pharmaceutical preparation for the treatment of influenza or other respiratory infection	ROMARK LABORATORIES, L.C.
	QUILIK Mexico Registered	App 25-APR-2015 App 1252229 Reg 25-APR-2015 Reg 1639957 Int'l Reg 1252229	Int'l Class 5 Pharmaceutical preparation for the treatment of influenza or other respiratory infection	ROMARK LABORATORIES, L.C.
	QUILIK Madrid Protocol Registered	App 25-APR-2015 App 1252229 Reg 25-APR-2015 Int'l Reg 1252229	Int'l Class 5 Pharmaceutical preparation for the treatment of influenza or other respiratory infection	ROMARK LABORATORIES, L.C.
	QUILIK New Zealand Registered	App 25-APR-2015 App 1252229 Reg 25-APR-2015 Reg 1021815 Int'l Reg 1252229	Int'l Class 5 Pharmaceutical preparation for the treatment of influenza or other respiratory infection	ROMARK LABORATORIES, L.C.